Seer Home (device for detecting epilepsy attacks)

2022: Start of wearable device sales

On September 26, 2022, the Australian company Seer Medical announced the launch of the Seer Home epilepsy diagnostic monitoring technology. The device will be sold in the United States after receiving appropriate approval from the authorities.

The regulator's decision was based on the successful results of a clinical trial conducted at the Mayo Clinic. The medical center gave Seer Medical an additional boost in early 2022, when the company was invited to the first class of a Platform_Accelerate program designed to support AI-focused startups in regulation, clinical research and business development.

Seer Home (device for detecting epilepsy attacks)

Given the green light to begin implementing its Seer Home system in the U.S., the company said it is now working to establish partnerships with hospitals and other health care facilities to begin reducing the number of potential epilepsy patients in the country who are waiting for long-term monitoring to confirm the diagnosis.

The Seer Home system combines a wearable device and a monitoring center to track the health of people with suspected epilepsy during the week, all done at home. The first of the components, the Seer Home device, has a number of electrodes that are attached to the chest and forehead, held in place by wearable parts that are located on the shoulders and top of the head, respectively. Electrodes take electroencephalograph (EEG) readings on brain activity and electrocardiogram (ECG). hearts

Data is automatically transmitted wirelessly to the connected hub. However, in addition to simply collecting EEG and ECG readings, the center is also equipped with cameras to monitor patients, with video recording of their body movements synchronized with electrode data to provide doctors with additional details about their condition. Seer Home AI algorithms are also able to analyze data for signs of epilepsy and potential disease triggers.

After a week of monitoring, Seer Home's equipment is returned to the company, which sends a doctor to analyze the collected information and conclusions of AI algorithms, and to produce an annotated report that can be sent to each patient's medical staff to help make an epilepsy diagnosis.

The ultimate goal of the company is to improve the accuracy of diagnosis of this disease: Although epilepsy affects more than 65 million people worldwide, about a third of diagnoses are made incorrectly. In addition, this disease is difficult to treat, since another third of epilepsy diagnoses are cases resistant to drug treatment regimens available in September 2022.^[1]

Notes